2.5 mg of semaglutide: what the starting dose does and why it matters

Why does semaglutide treatment begin at such a low dose?

Semaglutide activates GLP-1 receptors in the gut and brain, slowing the rate at which the stomach empties and reducing appetite signals. That mechanism is effective, but it can produce a wave of gastrointestinal discomfort (nausea, indigestion, loose stools) when the body first encounters it. Starting low gives your system time to adapt before the dose climbs toward therapeutic territory.

For the weekly Wegovy injection, the published schedule begins at 0.25 mg, not 2.5 mg. People searching for a 2.5 mg semaglutide dose are often thinking of the oral Wegovy tablet, approved by the MHRA in June 2026 as the first GLP-1 medicine licensed in the UK for weight management in tablet form. Its starting dose is 1.5 mg daily, rising through 4 mg and 9 mg to a 25 mg maintenance dose, the 2.5 mg figure sometimes appears in early coverage of the tablet and can create confusion. Whichever form your prescriber recommends, the principle is the same: the first dose exists to settle your system.

The 0.25 mg injectable starting dose and the oral 1.5 mg opening are both tolerability steps, the body's on-boarding. Expecting dramatic results in the first four weeks sets an unfair benchmark. Our prescribers hear this regularly from patients who worry something is wrong when the scale barely moves at week three. It is not wrong; it is deliberate.

What side effects are most common at the 2.5 mg semaglutide stage?

The side-effect profile at low doses mirrors what Wegovy produces at any stage, just usually milder. Nausea tops the list, often peaking in the day or two after the injection or tablet and easing as the week goes on. Some people notice constipation; others have the opposite. Burping, a sensation of fullness that arrives quickly at meals, and mild fatigue are also reported in the early weeks.

According to the NHS semaglutide patient information page, these gastrointestinal effects are the most frequently reported and are typically mild-to-moderate and transient. Staying well hydrated, eating smaller portions and not rushing meals all help. Fatty or very spicy food tends to worsen nausea at this stage, a practical tip worth knowing before the first injection day, which for many people lands on a weekday when work is already on the agenda.

Serious side effects are uncommon but need immediate attention. The MHRA highlighted acute pancreatitis as an infrequent but potentially serious risk associated with GLP-1 medicines: severe stomach pain that spreads toward the back, with or without vomiting, warrants urgent medical assessment. If you experience this, stop treatment and contact 111 or attend A&E. Any suspected side effect can be reported at Yellow Card, the MHRA's reporting service.

Does the 2.5 mg dose produce any weight loss at all?

Some people do notice a modest reduction in appetite and a small weight change in the first four weeks, particularly if their diet shifts naturally because food simply becomes less appealing. But the clinical evidence for meaningful weight loss is built around the maintenance dose of 2.4 mg weekly injection (or 25 mg daily tablet) sustained over months. The STEP 1 trial (a pivotal 68-week study published in the New England Journal of Medicine) found an average body-weight reduction of around 15% in adults on semaglutide 2.4 mg compared with placebo, alongside lifestyle changes. That result is built on reaching and staying at the therapeutic dose, not the starting one.

The full Wegovy dose ladder is designed so the majority of patients reach 2.4 mg (injection) or 25 mg (tablet) unless a dose is poorly tolerated, in which case the prescriber may pause the escalation or adjust the plan. Stopping early because the 2.5 mg stage produced little visible change would mean leaving most of the medicine's benefit untouched. If you are curious how costs shift across the dose steps, the Wegovy pricing page covers what to expect.

Who decides when to move beyond the starting dose?

The prescriber does. That sounds obvious, but it is the point that most differentiates a clinically supervised pathway from an unsupervised one. Dose escalation is not automatic or calendar-locked, it depends on how well the current dose is tolerated, any changes to your health, and whether the medicines programme is producing the expected response. Under NICE's guidance on semaglutide (TA875), if less than 5% weight loss is achieved after six months at the maintenance dose, continuing treatment is reviewed.

At nume, every repeat order is assessed by a GPhC-registered Independent Prescriber before it is dispensed. A real clinician reads your update; your consultation does not sit in an automated queue. If you are mid-treatment and have questions about where you are in the schedule, the semaglutide dosing guide covers the escalation logic in detail, and our clinical team is available seven days a week. When you are ready to explore whether treatment is right for you, the next step is a free consultation, there is no pressure and no commitment until a prescriber confirms suitability.